Total Payments
$186,696
2024 Payments
$10,995
Companies
29
Transactions
671
Medicare Patients
3,759
Medicare Billing
$932,111
Payment Breakdown by Category
Other$152,313 (81.6%)
Food & Beverage$19,678 (10.5%)
Travel$13,960 (7.5%)
Education$744.45 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $96,080 | 54 | 51.5% |
| Honoraria | $56,233 | 36 | 30.1% |
| Food and Beverage | $19,678 | 480 | 10.5% |
| Travel and Lodging | $13,960 | 84 | 7.5% |
| Education | $744.45 | 17 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Melinta Therapeutics, LLC | $82,164 | 174 | $0 (2024) |
| Merck Sharp & Dohme LLC | $30,289 | 137 | $0 (2024) |
| The Medicines Company | $29,598 | 58 | $0 (2017) |
| La Jolla Pharmaceutical Company | $22,426 | 50 | $0 (2024) |
| TETRAPHASE PHARMACEUTICALS, INC. | $15,734 | 29 | $0 (2020) |
| Astellas Pharma US Inc | $1,684 | 66 | $0 (2024) |
| Insmed, Inc. | $899.47 | 19 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $771.71 | 25 | $0 (2024) |
| Janssen Biotech, Inc. | $438.84 | 24 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $373.91 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,995 | 48 | Melinta Therapeutics, LLC ($6,478) |
| 2023 | $15,142 | 75 | Melinta Therapeutics, LLC ($13,001) |
| 2022 | $27,169 | 86 | Melinta Therapeutics, LLC ($15,742) |
| 2021 | $14,576 | 61 | La Jolla Pharmaceutical Company ($6,995) |
| 2020 | $4,660 | 34 | TETRAPHASE PHARMACEUTICALS, INC. ($3,384) |
| 2019 | $28,100 | 102 | TETRAPHASE PHARMACEUTICALS, INC. ($12,350) |
| 2018 | $44,187 | 141 | Melinta Therapeutics, Inc. ($36,173) |
| 2017 | $41,867 | 124 | The Medicines Company ($29,598) |
All Payment Transactions
671 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: ANTIBIOTIC | ||||||
| 12/12/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: ANTIBIOTICS | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/03/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $33.71 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/07/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Honoraria | Cash or cash equivalent | $1,785.00 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 11/07/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/30/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: CRITICAL CARE | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/25/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 09/25/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Food and Beverage | In-kind items and services | $116.07 | General |
| Category: ANTIBIOTICS | ||||||
| 09/25/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Travel and Lodging | Cash or cash equivalent | $18.76 | General |
| Category: ANTIBIOTICS | ||||||
| 09/25/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: ANTIFUNGALS | ||||||
| 09/11/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/09/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv | Food and Beverage | In-kind items and services | $115.22 | General |
| Category: ANTIBIOTICS | ||||||
| 08/20/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: ANTIBIOTIC | ||||||
| 08/20/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Vabomere | Food and Beverage | In-kind items and services | $5.87 | General |
| Category: ANTIBIOTICS | ||||||
| 08/16/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.26 | General |
| Category: Infectious Diseases | ||||||
| 07/31/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: ANTIFUNGALS | ||||||
| 07/30/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: HIV | ||||||
| 07/23/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: ANTIBIOTIC | ||||||
| 07/23/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $9.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/11/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Honoraria | Cash or cash equivalent | $1,785.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/11/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $129.15 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/11/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: ANTIBIOTICS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 986 | 3,418 | $585,714 | $249,179 |
| 2022 | 5 | 928 | 3,545 | $595,047 | $238,949 |
| 2021 | 6 | 798 | 2,773 | $473,101 | $193,873 |
| 2020 | 6 | 1,047 | 3,433 | $607,813 | $250,110 |
Total Patients
3,759
Total Services
13,169
Medicare Billing
$932,111
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 384 | 2,457 | $341,523 | $150,700 | 44.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 155 | 434 | $86,800 | $39,923 | 46.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 213 | 242 | $64,372 | $24,364 | 37.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 171 | 181 | $70,409 | $24,225 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 90 | $18,270 | $8,188 | 44.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $4,340 | $1,779 | 41.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 373 | 2,638 | $366,682 | $146,879 | 40.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 147 | 430 | $86,000 | $34,362 | 40.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 168 | 173 | $67,297 | $26,716 | 39.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 191 | 212 | $56,392 | $22,420 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 92 | $18,676 | $8,572 | 45.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 315 | 2,029 | $282,031 | $115,896 | 41.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 128 | 322 | $64,400 | $26,204 | 40.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 151 | 158 | $61,462 | $25,057 | 40.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 145 | 164 | $43,624 | $17,764 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 47 | 88 | $17,864 | $7,760 | 43.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $3,720 | $1,191 | 32.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 384 | 2,329 | $327,754 | $135,273 | 41.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 172 | 514 | $103,709 | $43,033 | 41.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 194 | 206 | $80,782 | $33,594 | 41.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 218 | 240 | $63,974 | $26,537 | 41.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 66 | 130 | $26,464 | $9,880 | 37.3% |
| 36589 | Removal of central venous catheter for infusion | Office | 2020 | 13 | 14 | $5,130 | $1,792 | 34.9% |
About Dr. Guillermo Padilla, M.D
Dr. Guillermo Padilla, M.D is a Infectious Disease healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1124229265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Guillermo Padilla, M.D has received a total of $186,696 in payments from pharmaceutical and medical device companies, with $10,995 received in 2024. These payments were reported across 671 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($96,080).
As a Medicare-enrolled provider, Padilla has provided services to 3,759 Medicare beneficiaries, totaling 13,169 services with total Medicare billing of $932,111. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Shreveport, LA
- Active Since 05/29/2007
- Last Updated 02/15/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1124229265
Products in Payments
- Kimyrsa (Drug) $41,554
- XERAVA (Drug) $23,566
- Vabomere (Drug) $21,024
- ZERBAXA (Drug) $20,971
- ORBACTIV (Drug) $19,606
- Xerava (Drug) $12,350
- Baxdela (Drug) $11,151
- Orbactiv (Drug) $8,038
- MINOCIN IV (Drug) $6,139
- DIFICID (Drug) $4,290
- VABOMERE (Drug) $3,853
- XACDURO (Drug) $2,094
- SIVEXTRO (Drug) $1,909
- Arikayce (Drug) $775.00
- NUZYRA (Drug) $771.71
- Cresemba (Drug) $555.20
- ACTHAR (Biological) $321.58
- VIBATIV (Drug) $307.09
- MYCAMINE (Drug) $305.55
- AVYCAZ (Drug) $278.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Shreveport
Jihad El-Hayek, M.d, M.D
Infectious Disease — Payments: $13,949
Infectious Disease $13,949
Gerardo Negron, Md, MD
Infectious Disease — Payments: $10,209
Infectious Disease $10,209
Dr. Mohammad Alam, Md, MD
Infectious Disease — Payments: $3,936
Infectious Disease $3,936
John Todd, M.d, M.D
Infectious Disease — Payments: $3,715
Infectious Disease $3,715
Raymond Coghlan, Md, MD
Infectious Disease — Payments: $850.28
Infectious Disease $850.28
John King, M.d, M.D
Infectious Disease — Payments: $63.78
Infectious Disease $63.78